欧州連合 - エストニア語 - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosupressandid - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

エストニア - エストニア語 - Ravimiamet

ciron drugs & pharmaceuticals pvt. ltd. - metoklopramiid - süstelahus - 5mg 1ml 2ml 100tk

エストニア - エストニア語 - Ravimiamet

supermax drugs & pharmaceuticals pvt. ltd. - kaaliumkloriid - toimeainet prolongeeritult vabastav tablett - 600mg 100tk

エストニア - エストニア語 - Ravimiamet

acme drugs s.r.l. - ivermektiin - ravimsööda eelsegu - 6mg 1g 5kg 1tk

欧州連合 - エストニア語 - EMA (European Medicines Agency)

novartis europharm limited - trametiniib - melanoom - antineoplastilised ained - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 ja 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. mitteväikerakk-kopsuvähk (mitteväikerakk-kopsuvähi)trametinib koos dabrafenib on näidustatud ravi täiskasvanud patsientidel, kaugelearenenud mitteväikerakk-kopsuvähi, mille braf v600 mutatsioon.

欧州連合 - エストニア語 - EMA (European Medicines Agency)

mundipharma corporation (ireland) limited - naloksooni vesinikkloriid dihüdraat - opioidiga seotud häired - kõik muud ravitoimingud - nyxoid on ette nähtud viivitamatuks manustamiseks erakorralise ravina teadaolevate või kahtlustatavate opioidide üleannustamise korral, mis väljendub nii hingamisteede ja / või kesknärvisüsteemi depressioonis kui mittemeditsiinilistes ja tervishoiuasutustes. nyxoid is indicated in adults and adolescents aged 14 years and over. nyxoid is not a substitute for emergency medical care.

エストニア - エストニア語 - Ravimiamet

glaxosmithkline (ireland) limited - amoksitsilliin+klavulaanhape - õhukese polümeerikattega tablett - 875mg+125mg 4tk; 875mg+125mg 16tk; 875mg+125mg 12tk; 875mg+125mg 10tk; 875mg+125mg 20tk; 875mg+125mg 24tk

エストニア - エストニア語 - Ravimiamet

first pharma oÜ - amoksitsilliin+klavulaanhape - õhukese polümeerikattega tablett - 875mg+125mg 30tk; 875mg+125mg 20tk; 875mg+125mg 24tk; 875mg+125mg 100tk; 875mg+125mg 12tk; 875mg+125mg 4tk; 875mg+125mg 2tk; 875mg+125mg 500tk; 875mg+125mg 14tk

エストニア - エストニア語 - Ravimiamet

glaxosmithkline (ireland) limited - lamotrigiin - närimis-/dispergeeruv tablett - 5mg 56tk; 5mg 50tk; 5mg 42tk; 5mg 60tk; 5mg 10tk

エストニア - エストニア語 - Ravimiamet

sandoz gmbh - amoksitsilliin - õhukese polümeerikattega tablett - 1000mg 10tk; 1000mg 100tk; 1000mg 12tk